| |
| |
|
| Insider
Information: |
Bentsur Ron |
| Relationship: |
Chairman & CEO, Direct... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
4,188,470 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$52,464 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
4,188,470 |
|
|
| Total
Value |
$52,464 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
Chief Executive Office... |
2015-04-06 |
777,209 |
|
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
CEO |
2007-08-21 |
20,101 |
|
0 |
Premium* |
|
|
Stemline Therapeutics Inc |
STML |
Director |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
Beyond Air Ord Shs |
XAIR |
Director |
2023-03-20 |
144,736 |
|
0 |
Premium* |
|
|
Nuvectis Pharma, Inc. |
NVCT |
Chairman & CEO, Direct... |
2024-05-14 |
3,246,424 |
2022-02-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
152 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-08-18 |
4 |
AS |
$5.83 |
$26,691 |
D/D |
(4,578) |
208,662 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • – |
2022-02-14 |
4 |
B |
$5.88 |
$47,040 |
D/D |
8,000 |
2,814,459 |
2.81 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2021-01-02 |
4 |
S |
$5.89 |
$33,573 |
D/D |
(5,700) |
183,936 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-08-06 |
4 |
AS |
$5.94 |
$36,777 |
D/D |
(6,192) |
255,596 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-08-25 |
4 |
AS |
$5.95 |
$9,406 |
D/D |
(1,580) |
189,636 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-08-21 |
4 |
AS |
$6.05 |
$19,651 |
D/D |
(3,246) |
195,105 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-07-29 |
4 |
AS |
$6.09 |
$26,731 |
D/D |
(4,343) |
279,156 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-08-04 |
4 |
AS |
$6.13 |
$22,369 |
D/D |
(3,649) |
265,407 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-08-03 |
4 |
AS |
$6.16 |
$23,489 |
D/D |
(3,814) |
269,056 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-08-05 |
4 |
AS |
$6.16 |
$22,286 |
D/D |
(3,619) |
261,788 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-07-30 |
4 |
AS |
$6.26 |
$21,404 |
D/D |
(3,418) |
275,738 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-07-27 |
4 |
AS |
$6.27 |
$30,807 |
D/D |
(4,917) |
278,582 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-07-31 |
4 |
AS |
$6.27 |
$17,970 |
D/D |
(2,868) |
272,870 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2021-02-11 |
4 |
S |
$6.28 |
$9,420 |
D/D |
(1,500) |
182,436 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-08-20 |
4 |
AS |
$6.29 |
$23,780 |
D/D |
(3,778) |
198,351 |
0 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2020-08-19 |
4 |
AS |
$6.32 |
$41,266 |
D/D |
(6,533) |
202,129 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • – |
2022-02-10 |
4 |
B |
$6.34 |
$53,890 |
D/D |
8,500 |
2,806,459 |
2.81 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2021-02-12 |
4 |
S |
$6.36 |
$148,945 |
D/D |
(23,419) |
182,436 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2024-05-10 |
4 |
B |
$6.40 |
$12,800 |
D/D |
2,000 |
3,244,484 |
3.15 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2023-03-20 |
4 |
B |
$6.48 |
$14,904 |
D/D |
2,300 |
144,736 |
2.39 |
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2022-06-30 |
4 |
S |
$6.53 |
$261,104 |
D/D |
(40,000) |
142,436 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2024-05-14 |
4 |
B |
$6.74 |
$13,076 |
D/D |
1,940 |
3,246,424 |
3.15 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2013-03-27 |
4 |
S |
$6.88 |
$214,869 |
D/D |
(31,231) |
465,805 |
0 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Chief Executive Officer |
• • – |
2013-04-05 |
4 |
S |
$6.93 |
$12,439 |
D/D |
(1,795) |
464,010 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-03-28 |
4 |
B |
$7.05 |
$28,200 |
D/D |
4,000 |
2,825,459 |
3.23 |
- |
|
152 Records found
|
|
Page 3 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
